

**In the Claims**

Please replace all prior versions and listings of claims in this application with the following list of claims:

1.-120. (Cancelled)

121. (New) A method for treating a subject having cancer comprising administering an immunostimulatory oligonucleotide comprising a nucleotide sequence of

5' TCG TCG TTT TGT CGT TTT GTC GTT 3' (SEQ ID NO: 246)

and one or more of carboplatin, paclitaxel, cisplatin, 5-fluorouracil, doxorubicin, taxol and gemcitabine in an amount effective to treat the cancer.

122. (New) The method of claim 121, wherein the immunostimulatory oligonucleotide consists of the nucleotide sequence of

5' TCG TCG TTT TGT CGT TTT GTC GTT 3' (SEQ ID NO: 246).

123. (New) The method of claim 121, wherein the immunostimulatory oligonucleotide is up to 100 nucleotides in length.

124. (New) The method of claim 121, wherein the immunostimulatory oligonucleotide is 24-40 nucleotides in length.

125. (New) The method of claim 121 or 122, wherein the immunostimulatory oligonucleotide has a nucleotide backbone which includes at least one backbone modification.

126. (New) The method of claim 125, wherein the backbone modification is a phosphorothioate modification.

127. (New) The method of claim 125, wherein the nucleotide backbone is entirely modified.

128. (New) The method of claim 121 or 122, wherein the immunostimulatory oligonucleotide is administered by injection.

129. (New) The method of claim 121 or 122, wherein the subject is a human.

130. (New) The method of claim 121, wherein the cancer is non-small cell lung cancer.

131. (New) The method of claim 130, wherein the subject is administered carboplatin and paclitaxel.

132. (New) The method of claim 131, wherein the immunostimulatory oligonucleotide is 24-40 nucleotides in length.

133. (New) The method of claim 132, wherein the immunostimulatory oligonucleotide has a nucleotide backbone which includes at least one backbone modification.

134. (New) The method of claim 133, wherein the backbone modification is a phosphorothioate modification.

135. (New) The method of claim 134, wherein the nucleotide backbone is entirely modified.

136. (New) The method of claim 135, wherein the immunostimulatory oligonucleotide is administered by injection.

137. (New) The method of claim 136, wherein the subject is a human.

138. (New) The method of claim 137, wherein the immunostimulatory oligonucleotide consists of the nucleotide sequence of

5' TCG TCG TTT TGT CGT TTT GTC GTT 3' (SEQ ID NO: 246).